Laurus Labs is coming out with an initial public offering (IPO) to raise up to Rs 300 crore in a price band Rs 426-428 per share. The issue will open for subscription on December 6, 2016 and will close on December 8, 2016.
Shares of the company are proposed to be listed on NSE and BSE both. The Book Running Lead Managers (BRLMs) to the offer are Kotak Mahindra Capital Company, Citigroup Global Markets India, Jefferies India and SBI Capital Markets. The firm proposes to use the net proceeds from the fresh issue towards pre-payment of term loans and general corporate purposes.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus Labs also manufactures APIs in oncology and other therapeutic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1824.00 |
| Dr. Reddys Lab | 1267.80 |
| Cipla | 1355.80 |
| Zydus Lifesciences | 1074.30 |
| Lupin | 2327.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: